# VEXAS Syndrome FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/vexas-syndrome

> 4 upcoming FDA catalysts in VEXAS Syndrome: OJJAARA (momelotinib, GSK) on Dec 2028 to Mar 2029 (topline data readout); arumakimig (NVS) on Dec 2028 to Mar 2029 (topline data readout); OJJAARA (momelotinib, GSK) on December 2028 (primary completion); arumakimig (NVS) on December 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2028 to Mar 2029 | [OJJAARA (momelotinib) topline data readout](https://sec-api.dev/pdufa/momelotinib) | GSK | VEXAS Syndrome | scheduled | "NCT07569081 (A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07569081)) |
| Dec 2028 to Mar 2029 | [Arumakimig topline data readout](https://sec-api.dev/pdufa/arumakimig) | NVS | VEXAS Syndrome | scheduled | "NCT07748624 (A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07748624)) |
| December 2028 | [OJJAARA (momelotinib) primary completion](https://sec-api.dev/pdufa/momelotinib) | GSK | VEXAS Syndrome | scheduled | "NCT07569081 (A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07569081)) |
| December 2028 | [Arumakimig primary completion](https://sec-api.dev/pdufa/arumakimig) | NVS | VEXAS Syndrome | scheduled | "NCT07748624 (A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07748624)) |

## Drugs

- [OJJAARA (momelotinib)](https://sec-api.dev/pdufa/momelotinib) (GSK)
- [Arumakimig](https://sec-api.dev/pdufa/arumakimig) (NVS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/vexas-syndrome.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VEXAS Syndrome FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/vexas-syndrome

```bibtex
@misc{secapidev_indications_vexas_syndrome_20261116,
  title        = {VEXAS Syndrome FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/vexas-syndrome}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_vexas_syndrome_20261116","title":"VEXAS Syndrome FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/vexas-syndrome","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
